Stock listing

NASDAQ:ODTX Odyssey Therapeutics, Inc. Stock

Home listing (NASDAQ) of Odyssey Therapeutics, Inc.

Follow Odyssey Therapeutics, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:ODTX

$16.96 USD -2.02 (-10.6%)

Close on Nov 20, 2026

Past 6 months -5.8% · daily closes, May 7, 2026 – Nov 20, 2026, adjusted for splits
Day range
$16.46 – $18.08 USDNov 20, 2026
Volume
677,842 sharesNov 20, 2026
Market cap
$815.2M USDAt the close on Nov 20, 2026 · price × 48.07M shares outstanding
Traded on an average day
$6.86M USDMedian day 255,200 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:ODTX · Home$16.96 USD-2.02 (-10.6%)677,842$17.65$18.08$16.46$18.98Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:ODTX · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$16.96-2.02-10.6%$17.65$18.08$16.46677,842
$18.98-0.39-2.0%$19.26$19.98$18.82369,096
$19.37+0.01+0.1%$19.38$19.71$18.91301,614
$19.36+0.22+1.1%$18.87$19.67$18.57340,246
$19.14-0.96-4.8%$19.76$19.76$18.46322,921
$20.10-0.89-4.2%$20.81$20.81$19.08321,972
$20.99+0.99+4.9%$19.98$21.21$19.22245,072
$20.00+0.85+4.4%$18.98$20.86$18.71395,007
$19.15-0.08-0.4%$19.53$19.72$18.38621,338
$19.23+0.35+1.9%$18.99$19.70$18.01577,256
$18.88-0.62-3.2%$19.50$19.81$18.37433,829
$19.50-2.07-9.6%$21.89$22.36$19.00675,498
$21.57+2.04+10.4%$19.72$21.77$19.70412,225
$19.53-0.01-0.1%$19.83$20.66$18.72258,944
$19.54-0.29-1.5%$19.77$20.20$19.12166,398
$19.83+0.29+1.5%$19.70$20.62$18.70212,829
$19.54+0.04+0.2%$19.33$20.07$19.19210,309
$19.50+0.20+1.0%$19.37$19.98$18.74241,163
$19.30-0.30-1.5%$19.60$19.68$18.62139,918
$19.60+0.52+2.7%$19.02$20.07$18.37209,300
$19.08+0.08+0.4%$18.84$19.32$18.52141,800
$19.00+0.01+0.1%$18.93$19.79$18.00255,300
$18.99+0.89+4.9%$17.79$19.73$16.93317,300
$18.10+0.93+5.4%$16.94$18.50$16.94300,400
$17.17-0.40-2.3%$17.45$17.50$16.90219,400
$17.57+0.97+5.8%$16.62$17.75$16.36159,000
$16.60-0.64-3.7%$16.87$17.35$16.51245,600
$17.24-1.02-5.6%$18.15$18.40$17.18258,800
$18.26-0.74-3.9%$18.88$19.15$18.16282,700
$19.00+0.88+4.9%$18.72$19.65$18.49325,600
$18.12+0.04+0.2%$17.83$18.38$17.13414,200
$18.08-0.05-0.3%$18.01$18.84$17.83264,100
$18.13-2.71-13.0%$20.84$20.84$18.06340,700
$20.84+0.11+0.5%$20.52$20.96$19.73171,800
$20.73+0.31+1.5%$20.67$21.60$20.05192,500
$20.42-1.80-8.1%$21.98$22.36$20.33308,400
$22.22-0.22-1.0%$22.48$23.50$21.70334,200
$22.44+0.97+4.5%$21.47$22.76$21.21201,700
$21.47+0.96+4.7%$20.02$21.65$19.72213,100
$20.51+0.58+2.9%$19.90$20.88$19.41237,800
$19.93-0.83-4.0%$20.77$21.09$18.77396,000
$20.76-2.58-11.1%$22.99$23.03$20.53255,200
$23.34+0.28+1.2%$23.36$24.33$22.70555,200
$23.06-1.32-5.4%$24.51$25.22$23.05245,700
$24.38+1.16+5.0%$23.35$25.15$22.882,604,300
$23.22+0.10+0.4%$23.46$25.81$22.94524,200
$23.12+1.13+5.1%$22.18$23.40$21.82591,200
$21.99-2.27-9.4%$24.31$24.84$21.72276,700
$24.26-0.37-1.5%$24.69$25.29$23.37219,000
$24.63+0.99+4.2%$23.94$25.14$23.64198,400
$23.64-0.87-3.5%$24.09$25.38$23.50192,700
$24.51-2.46-9.1%$26.97$28.26$24.24217,400
$26.97-1.79-6.2%$28.30$28.87$26.89174,700
$28.76+2.36+8.9%$26.24$29.05$25.71269,000
$26.40-0.22-0.8%$26.88$27.27$25.62189,600
$26.62+2.12+8.7%$24.80$26.80$24.80171,400
$24.50-0.02-0.1%$24.21$25.23$24.06172,800
$24.52+0.16+0.7%$24.33$24.80$22.89170,400
$24.36-1.62-6.2%$26.05$26.52$24.25117,300
$25.98+0.36+1.4%$25.82$26.40$25.48141,400
$25.62-0.61-2.3%$26.50$27.33$24.87235,700
$26.23+1.08+4.3%$25.12$27.32$25.12163,722
$25.15-1.24-4.7%$26.39$28.00$25.05257,413
$26.39+1.72+7.0%$24.91$26.49$24.55181,300
$24.67+0.42+1.7%$24.40$24.77$23.07121,600
Ticker
NASDAQ:ODTX
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Odyssey Therapeutics, Inc. news

Odyssey Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
11 in the last 12 months · 11 in all · newest Nov 10, 2026 · oldest 2026
Decks
4 decks · latest Oct 20, 2026

Where Odyssey Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:ODTX · Home listing · This pageNASDAQUnited StatesUSD
BOATS:ODTXBOATSUnited StatesUSD

Valuation

Price/book 2.2× against a median of 3.7×: the lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$512.7M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
2.2×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.1×
Beta vs S&P 500
1.11

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Odyssey Therapeutics, Inc. · NASDAQ:ODTXUS$815.2MUS$512.7Mn/an/an/a2.2×n/a0.1×1.11
Latigo Biotherapeutics, Inc. · NASDAQ:LTGOUS$861.9MUS$460.7Mn/an/an/a2.2×n/a0.0×n/a
Pharming Group NV · EURONEXT:PHARMUS$840.2MUS$766.4M34.4×2.0×19.8×2.9×6.3%0.4×n/a
Corvus Pharmaceuticals, Inc. · NASDAQ:CRVSUS$815.7MUS$613.4Mn/an/an/a3.9×n/a0.0×1.64
NATURECELL Co., Ltd. · KRX:007390US$798.8MUS$783.0Mn/a51.4×n/a17.1×−13.2%0.0×n/a
Arbutus Biopharma Corporation · NASDAQ:ABUSUS$796.4MUS$458.9M3.6×2.5×3.1×9.3×121.2%0.0×1.10
Genfleet Therapeutics (Shanghai), Inc. Class H · HKEX:2595US$787.5MUS$518.8Mn/a26.5×n/a3.3×n/a0.0×n/a
Shaanxi Micot Pharmaceutical Technology Co., Ltd. Class H · HKEX:2335US$778.7MUS$599.6Mn/an/an/a5.5×n/a0.0×n/a
Ironwood Pharmaceuticals, Inc. · NASDAQ:IRWDUS$778.1MUS$702.9M5.2×1.8×n/an/a37.4%n/a1.16
Syndax Pharmaceuticals, Inc. · NASDAQ:SNDXUS$772.7MUS$695.6Mn/a2.4×n/an/a−72.4%n/a0.64
MeiraGTx Holdings plc · NASDAQ:MGTXUS$766.4MUS$715.6M9.8×1.8×3.7×3.6×19.5%0.6×1.57
Median of the othersUS$791.9MUS$654.5M7.5×2.4×3.7×3.7×12.9%0.0×1.16

Forecasts

Analysts' consensus from EODHD, read Nov 17, 2026. Not 6ix's view and not investment advice.

Price target
34.67 USD · Analysts' mean
EPS, year to Dec 2026
-5.60 · 2 analysts

Team and board

OfficerRole
Gary D. GlickFounder, President & CEO

Events

QuarterResultsShare move
Q3 2026Nov 4, 2026 · Before open−9.6%
Q2 2026Aug 5, 2026+8.0%
Q1 2026Jun 3, 2026+0.4%

Open Events

Decks

DeckKindSlidesDate
UEG Week 2026 Investor WebcastConference47 slidesOct 20, 2026
Investor Presentation (October 2026)Investor deck45 slidesOct 20, 2026
Investor Presentation (September 2026)Investor deck41 slidesSeptember 2026
Investor Presentation (June 2026)Investor deck40 slidesJun 23, 2026

Open Decks

Financings

RaiseDate
Public offering of common stock
Closed: US$18 a share
Use of proceeds: Advance OD-001 and the broader portfolio, including SLC15A4 inhibitor OD-002
Jun 17, 2026
Private placement of common stock
Closed: US$18 a share
Jun 17, 2026

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$18.00 a share on May 7, 2026.

Price
US$18.00 a share
Shares offered
15,500,000 shares of common stock
Offering size
US$279 million
Underwriters' option
Up to 2,325,000 more shares
Listing
ODTX on the Nasdaq Capital Market
Underwriters
J.P. Morgan, TD Cowen, Cantor, Wedbush PacGrow, Oppenheimer & Co. · In the order on the cover
Shares delivered
On or about May 11, 2026

Steps

StepWhen
Draft sent to the SEC in confidenceFeb 6, 2026
Filed publiclyApr 17, 2026
Amended onceMay 4, 2026
Shares registered with an exchangeMay 5, 2026
Declared effective by the SECMay 7, 2026
Final prospectus, with the priceMay 8, 2026

Open IPO · From the cover of the final prospectus (424B4) filed May 8, 2026

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022
Revenue2.98M4.47M1.04M0
Gross profit2.98M
Research and development126.6M112.6M112.3M101.8M
Selling, general and administrative37.5M27.1M22.2M21.0M
Operating income-161.2M-135.2M-133.4M-122.8M
Depreciation and amortization4.91M5.19M4.91M2.76M
EBITDA-156.2M-130.0M-128.5M-120.0M
Interest expense17.0K18.0K335.0K291.0K
Income before tax-149.6M-128.9M-125.5M-124.3M
Income tax-927.0K
Net income-148.6M-129.3M-125.9M-124.7M
Earnings per share, basic-5.39-2.74-2.67-2.64

Balance sheet

LineFY2025FY2024FY2023FY2022
Cash and equivalents41.7M59.1M52.5M241.0M
Short-term investments139.7M70.2M134.5M0
Current assets190.7M135.5M192.5M248.7M
Goodwill14.3M13.3M13.6M12.9M
Total assets269.8M197.4M286.5M317.1M
Accounts payable7.87M6.32M7.73M8.05M
Current liabilities26.5M28.4M22.1M22.8M
Long-term debt4.76M
Total debt27.1M
Total liabilities758.1M580.0M549.2M461.8M
Shareholders' equity-488.3M-382.5M-262.7M-144.6M
Shares outstanding27.6M47.2M47.2M47.2M

Cash flow

LineFY2025FY2024FY2023FY2022
Cash from operations-129.5M-117.5M-112.7M-99.8M
Capital spending-1.23M-764.0K-5.06M-13.0M
Free cash flow-130.7M-118.2M-117.8M-112.9M
Cash from investing-103.9M
Cash from financing215.6M27.0M92.1M182.7M
Change in cash-17.4M6.34M-185.7M69.8M

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G/A · Big-stake notice, amendedNov 5, 2026Big-stake noticeSEC
10-Q · Quarterly reportNov 4, 2026Quarterly reportSEC
8-K · Current reportNov 4, 2026ResultsSEC
8-K · Current reportOct 20, 2026Current reportSEC
8-K · Current reportSep 8, 2026Current reportSEC
10-Q · Quarterly reportAug 5, 2026Quarterly reportSEC
8-K · Current reportAug 4, 2026ResultsSEC
8-K · Current reportJun 23, 2026Current reportSEC
10-Q · Quarterly reportJun 17, 2026Quarterly reportSEC
8-K · Current reportJun 17, 2026ResultsSEC
All 72 filings
FilingDateTypeFiled with
SCHEDULE 13G · Big-stake noticeJun 5, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeMay 18, 2026Big-stake noticeSEC
SCHEDULE 13D · Big-stake noticeMay 18, 2026Big-stake noticeSEC
SCHEDULE 13D · Big-stake noticeMay 18, 2026Big-stake noticeSEC
SCHEDULE 13D · Big-stake noticeMay 15, 2026Big-stake noticeSEC
SCHEDULE 13D · Big-stake noticeMay 15, 2026Big-stake noticeSEC
4 · Change in ownershipMay 13, 2026Insider tradeSEC
4 · Change in ownershipMay 12, 2026Insider tradeSEC
3 · Initial statement of ownershipMay 12, 2026Insider tradeSEC
4 · Change in ownershipMay 11, 2026Insider tradeSEC
4 · Change in ownershipMay 11, 2026Insider tradeSEC
4 · Change in ownershipMay 11, 2026Insider tradeSEC
4 · Change in ownershipMay 11, 2026Insider tradeSEC
4 · Change in ownershipMay 11, 2026Insider tradeSEC
4 · Change in ownershipMay 11, 2026Insider tradeSEC
4 · Change in ownershipMay 11, 2026Insider tradeSEC
4 · Change in ownershipMay 11, 2026Insider tradeSEC
4 · Change in ownershipMay 11, 2026Insider tradeSEC
4 · Change in ownershipMay 11, 2026Insider tradeSEC
4 · Change in ownershipMay 11, 2026Insider tradeSEC
4 · Change in ownershipMay 11, 2026Insider tradeSEC
4 · Change in ownershipMay 11, 2026Insider tradeSEC
8-K · Current reportMay 11, 2026Material contractSEC
S-8 · Registration statement for employee plansMay 8, 2026Offer documentSEC
424B4 · ProspectusMay 8, 2026Offer documentSEC
EFFECT · Notice that a registration is effectiveMay 8, 2026Other filingsSEC
3 · Initial statement of ownershipMay 7, 2026Insider tradeSEC
3 · Initial statement of ownershipMay 7, 2026Insider tradeSEC
3 · Initial statement of ownershipMay 7, 2026Insider tradeSEC
3 · Initial statement of ownershipMay 7, 2026Insider tradeSEC
3 · Initial statement of ownershipMay 7, 2026Insider tradeSEC
3 · Initial statement of ownershipMay 7, 2026Insider tradeSEC
3 · Initial statement of ownershipMay 7, 2026Insider tradeSEC
3 · Initial statement of ownershipMay 7, 2026Insider tradeSEC
3 · Initial statement of ownershipMay 7, 2026Insider tradeSEC
3 · Initial statement of ownershipMay 7, 2026Insider tradeSEC
3 · Initial statement of ownershipMay 7, 2026Insider tradeSEC
3 · Initial statement of ownershipMay 7, 2026Insider tradeSEC
3 · Initial statement of ownershipMay 7, 2026Insider tradeSEC
3 · Initial statement of ownershipMay 7, 2026Insider tradeSEC
3 · Initial statement of ownershipMay 7, 2026Insider tradeSEC
3 · Initial statement of ownershipMay 7, 2026Insider tradeSEC
3 · Initial statement of ownershipMay 7, 2026Insider tradeSEC
3 · Initial statement of ownershipMay 7, 2026Insider tradeSEC
S-1MEF · Registration of more shares for the same offeringMay 7, 2026Offer documentSEC
CERT · Exchange's certificate of listingMay 7, 2026Other filingsSEC
8-A12B · Registration of shares for listing on an exchangeMay 5, 2026Other filingsSEC
S-1/A · Registration statement, amendedMay 4, 2026Offer documentSEC
S-1 · Registration statementApr 17, 2026Offer documentSEC
DRS/A · Draft registration statement, amendedApr 3, 2026Offer documentSEC
DRS/A · Draft registration statement, amendedMar 16, 2026Offer documentSEC
DRS · Draft registration statementFeb 6, 2026Offer documentSEC
DDec 4, 2025Other filingsSEC
RW · Request to withdraw a registrationJun 9, 2025Other filingsSEC
S-1 · Registration statementJan 17, 2025Offer documentSEC
DRS/A · Draft registration statement, amendedDec 5, 2024Offer documentSEC
DRS/A · Draft registration statement, amendedNov 15, 2024Offer documentSEC
DRS · Draft registration statementOct 4, 2024Offer documentSEC
D/AAug 14, 2024Other filingsSEC
DDec 15, 2023Other filingsSEC
DOct 27, 2022Other filingsSEC
DOct 14, 2021Other filingsSEC

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Odyssey Therapeutics, Inc.’s releases · as of Nov 2, 2026

Common shares
48,067,877
Fully diluted
48,067,877

Fully diluted

LineSharesAs of
Common shares48,067,877Nov 2, 2026

Share count over time

CountShares
Nov 2, 202648,067,877

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueChange vs Jun 30Filed
Fidelity6.24M13.0%US$136M+1.06MNov 10, 2026
Sr One Capital Management, LP3.79M7.9%US$84.3MNo changeNov 16, 2026
Tpg Gp A, LLC3.69M7.7%US$82MNo changeNov 16, 2026
Lightspeed Management Company, L.L.C.3.61M7.5%US$80.2MNo changeNov 13, 2026
Orbimed Advisors LLC3M6.2%US$66.7MNo changeNov 16, 2026
Sanofi1.99M4.1%US$44.2M−1,718Nov 5, 2026
Mpm Bioimpact LLC1.29M2.7%US$28.6MNewNov 16, 2026
Affinity Asset Advisors, LLC1.26M2.6%US$28M+494KNov 13, 2026
BlackRock1.14M2.4%US$25.4M+903KNov 13, 2026
Deerfield Management Company, L.P.1.05M2.2%US$23.2MNo changeNov 16, 2026
Show 50 holders
HolderSharesOf the companyValueChange vs Jun 30Filed
Vanguard964K2.0%US$21.4M+121KNov 13, 2026
Woodline Partners LP912K1.9%US$20.3M+567KNov 16, 2026
Sands Capital Alternatives, LLC875K1.8%US$19.4MNo changeNov 13, 2026
Logos Global Management LP846K1.8%US$18.8M+324KNov 19, 2026
Hhlr Advisors, LTD.832K1.7%US$18.5MNo changeNov 16, 2026
General Catalyst Group Management, LLC810K1.7%US$18MNo changeNov 16, 2026
Foresite Capital Management V, LLC730K1.5%US$16.2M+16,497Nov 16, 2026
Vivo Capital, LLC575K1.2%US$12.8MNo changeNov 13, 2026
EcoR1 Capital, LLC556K1.2%US$12.3MNo changeNov 16, 2026
T. Rowe Price492K1.0%US$10.9M+19,940Nov 16, 2026
Catalio Capital Management, LP458K0.95%US$10.2MNo changeNov 16, 2026
Geode Capital425K0.88%US$9.45M+236KNov 6, 2026
Adage Capital Partners Gp, L.L.C.400K0.83%US$8.89M−325KNov 16, 2026
Redmile Group, LLC375K0.78%US$8.32M−50,490Nov 16, 2026
State Street309K0.64%US$6.87MNewNov 12, 2026
Marshall Wace, LLP297K0.62%US$6.6M−196KNov 13, 2026
Franklin Templeton275K0.57%US$5.36MNo changeNov 12, 2026
Two Sigma202K0.42%US$4.48M+45,233Nov 16, 2026
Siren, L.L.C.200K0.42%US$4.44MNo changeNov 12, 2026
Schwab151K0.31%US$3.36M+49,599Nov 16, 2026
Northern Trust127K0.27%US$2.83M+92,848Nov 16, 2026
Cormorant Asset Management, LP125K0.26%US$2.78M−50,000Nov 16, 2026
Citadel99,9260.21%US$2.22M−123KNov 16, 2026
abrdn79,9440.17%US$1.78M−85,056Nov 10, 2026
Seven Grand Managers, LLC50,0000.10%US$1.11MNo changeNov 16, 2026
Ensign Peak Advisors, Inc48,2420.10%US$1.07M−16,379Nov 12, 2026
XTX Topco Ltd40,4520.08%US$899K+23,900Nov 16, 2026
BNY37,5450.08%US$834KNewNov 5, 2026
Manufacturers Life Insurance Company, The37,2410.08%US$827K+5,116Nov 13, 2026
Bank of America35,4990.07%US$789KNewNov 16, 2026
Hudson Bay Capital Management LP30,0000.06%US$667K−42,918Nov 13, 2026
TD29,1340.06%US$654KNo changeNov 13, 2026
Millennium26,3920.05%US$586KNewNov 16, 2026
Ghisallo Capital Management LLC25,0000.05%US$556KNo changeNov 19, 2026
Nuveen22,9730.05%US$510KNewNov 10, 2026
Morgan Stanley16,0340.03%US$356K+14,262Nov 13, 2026
Rhumbline Advisers15,1090.03%US$336KNewNov 10, 2026
DWS14,1060.03%US$313KNewNov 6, 2026
Invesco13,7060.03%US$305KNewNov 12, 2026
Citigroup Inc12,3170.03%US$274K+11,806Nov 4, 2026

This page holds 50 of 71 holders. Open Shareholders

Funds

HolderSharesOf the companyValueChangeAs of
Fidelity Growth Company Fund596K1.2%US$10.1MNewMay 31, 2026
Vanguard Total Stock Market Index Fund531K1.1%US$9.94MNewJun 30, 2026
Select Biotechnology Portfolio340K0.71%US$5.77MNewMay 31, 2026
T. Rowe Price Health Sciences Fund, Inc.183K0.38%US$3.42MNewJun 30, 2026
Vanguard Extended Market Index Fund180K0.37%US$3.36MNewJun 30, 2026
Fidelity Growth Company K6 Fund165K0.34%US$2.8MNewMay 31, 2026
Fidelity Series Growth Company Fund147K0.31%US$2.51MNewMay 31, 2026
Franklin Biotechnology Discovery Fund99,8260.21%US$1.89MNewJul 31, 2026
Schwab Total Stock Market Index Fund15,0000.03%US$284KNewJul 31, 2026
Vanguard Russell 2000 Index Fund11,8830.02%US$202KNewMay 31, 2026
All 20 holders
HolderSharesOf the companyValueChangeAs of
T. Rowe Price Health Sciences Portfolio11,2760.02%US$211KNewJun 30, 2026
Health Sciences Trust7,8990.02%US$148KNewJun 30, 2026
Blackstone Alternative Multi-Strategy Fund6,5750.01%US$123KNewJun 30, 2026
Vanguard Institutional Total Stock Market Index Fund6,4420.01%US$121KNewJun 30, 2026
EQ/T.Rowe Price Health Sciences Portfolio5,5710.01%US$104KNewJun 30, 2026
Vanguard Balanced Index Fund3,243<0.01%US$60,677NewJun 30, 2026
Vanguard Russell 2000 Growth Index Fund1,169<0.01%US$19,885NewMay 31, 2026
Tiff Multi-Asset Fund1,052<0.01%US$19,683NewJun 30, 2026
Vanguard Russell 2000 Value Index Fund438<0.01%US$7,450NewMay 31, 2026
Vanguard Russell 3000 Index Fund195<0.01%US$3,317NewMay 31, 2026

Insider trades

InsiderTradeSharesPriceValueDate
Coulter James G
Other: Former 10% Owner
Buy1,388,889USD 18.00US$25MMay 11, 2026
Chu Shelley
Director
Buy11,111USD 18.00US$200KMay 11, 2026
Nan Li
Director
Buy1,111,111USD 18.00US$20MMay 11, 2026
George Simeon
10% owner
Sale1,065USD 18.00US$19,170May 11, 2026
George Simeon
10% owner
Buy222,222USD 18.00US$4MMay 11, 2026
George Simeon
10% owner
Sale277USD 18.00US$4,986May 11, 2026
George Simeon
10% owner
Buy133,333USD 18.00US$2.4MMay 11, 2026
George Simeon
10% owner
Sale438USD 18.00US$7,884May 11, 2026
George Simeon
10% owner
Buy200,000USD 18.00US$3.6MMay 11, 2026
Dimension Capital II, L.P.
Director
Buy1,111,111USD 18.00US$20MMay 8, 2026
All 12 trades
InsiderTradeSharesPriceValueDate
Haas Jason
Officer: Chief Financial Officer
Buy1,000USD 20.00US$20,000May 8, 2026
Leiden Jeffrey M
Director
Buy5,000USD 20.00US$100KMay 8, 2026

Big stakes

HolderStakeSharesDate
FMR LLC13.00%6.24MSep 30, 2026
SR One Capital Management, LLC8.00%3.79MMay 11, 2026
Tpg Gp A, LLC7.80%3.69MMay 11, 2026
Jeito II S.L.P.7.80%3.69MMay 8, 2026
Lightspeed Venture Partners XV-B (Ignite), L.P.7.60%3.61MMay 11, 2026
Dimension Capital II, L.P.7.10%3.33MMay 8, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Timothy P. Walbert
Other companies: Latigo Biotherapeutics, Inc. (Chair, Board of Directors · Since at least Aug 6, 2026); Kardigan, Inc. (Board of Directors · Since at least Jun 17, 2026); BioMarin Pharmaceutical Inc. (Director · Since at least Feb 24, 2025); Sagimet Biosciences Inc. - Series A (Director · Since at least Apr 1, 2024); Mirum Pharmaceuticals, Inc. (Director · Since at least Apr 5, 2023); Century Therapeutics, Inc. (Director · Since at least Oct 1, 2022); Aurinia Pharmaceuticals Inc (Director · Jan 1, 2021 – May 18, 2022 · Past); Assertio Holdings, Inc. (Director · May 20, 2020 – May 20, 2020 · Past); Exicure, Inc. (Director · Jul 22, 2019 – Jun 2, 2021 · Past); Sucampo Pharmaceuticals Inc (Director · Oct 12, 2015 – Feb 13, 2018 · Past); Egalet Corporation (Director · Mar 10, 2014 – May 20, 2020 · Past); Horizon Pharma PLC (Chairman, President and CEO, Director · Jul 28, 2011 – Mar 23, 2019 · Past); Raptor Pharmaceutical Corp (Director · Apr 11, 2011 – Mar 13, 2014 · Past); Idm Pharma Inc (President and CEO, Director · May 25, 2007 – Apr 3, 2008 · Past)
Director · Since at least May 7, 2026
Ian Smith
Other companies: Stoke Therapeutics, Inc. (Chief Executive Officer & Director · Since at least Sep 19, 2023); Foghorn Therapeutics Inc. (Director · Since at least Apr 27, 2021); Solid Biosciences Inc. (Chairman of the Board · Since at least Apr 15, 2020); IVERIC bio Inc (Director · Aug 2, 2016 – Aug 2, 2016 · Past); Acorda Therapeutics Inc (Director · Feb 1, 2007 – Jun 27, 2018 · Past); Vertex Pharmaceuticals Incorporated (EVP, COO · Jan 23, 2006 – Jun 29, 2018 · Past)
Director · Since at least May 7, 2026
Jeffrey Leiden
Other companies: Vertex Pharmaceuticals Incorporated (Executive Chairman · Since at least Jul 21, 2015); Revolution Healthcare Acquisition Corp (Director · Mar 17, 2021 – Mar 17, 2021 · Past); Quest Diagnostics Incorporated (Director · Jul 1, 2015 – May 29, 2018 · Past)
Director · Since at least May 7, 2026
Carolyn Ng
Other companies: Bicara Therapeutics Inc. (Director · Sep 12, 2024 – Sep 12, 2024 · Past); Bicycle Therapeutics PLC (Director · May 22, 2019 – May 28, 2019 · Past)
Director · Since at least May 7, 2026
Jason Haas
Other companies: Ligand Pharmaceuticals Incorporated (Director · Since at least Jun 29, 2022); Syros Pharmaceuticals, Inc. (Chief Financial Officer · Oct 12, 2021 – Nov 18, 2024 · Past)
Chief Financial Officer · Since at least May 7, 2026
Ourania Tatsis
Other companies: Verve Therapeutics Inc (Director · Since at least Jun 26, 2024); Vertex Pharmaceuticals Incorporated (EVP, Chief Reg. & Quality Off. · Since at least Oct 1, 2019)
Director · Since at least May 7, 2026
Paulina Hill
Other companies: Neuronetics, Inc. (Director · Jun 27, 2018 – Jul 2, 2018 · Past); Kala Bio, Inc. (Director · Jul 19, 2017 – Jun 12, 2018 · Past)
Director · Since at least May 7, 2026
Jolie Siegel
Other companies: C4 Therapeutics, Inc. (Chief Legal Officer · Oct 1, 2020 – Feb 13, 2025 · Past)
See Remarks · Since at least May 7, 2026
Shelley Chu
Other companies: Hillevax Inc (Director · Since at least Apr 28, 2022)
Director · Since at least May 7, 2026
Valerie Odegard
Other companies: ARS Pharmaceuticals, Inc. (President and CSO · Dec 3, 2020 – May 2, 2022 · Past)
Director · Since at least May 7, 2026
All 16 people
PersonSeat
Anthony W OpipariSee Remarks · Since at least May 7, 2026
Aranicki Ksenija PavleticDirector · Since at least May 7, 2026
Collin M ToddSee Remarks · Since at least May 7, 2026
Gary D. GlickFounder, President & CEO · Since at least May 7, 2026
Nan LiDirector · Since at least May 7, 2026
Natalie DalesSee Remarks · Since at least May 7, 2026

Open People

Log in to ask 6ix AI your own questions about Odyssey Therapeutics, Inc.